LA JOLLA, Calif., April 20, 2016 /PRNewswire/ -- DermTech, Inc., an emerging diagnostics company focusing on non-invasive gene expression tests for skin cancer and inflammatory skin conditions, announced today that the College of American Pathologists (CAP) has awarded accreditation to its La Jolla, California clinical laboratory based on the results of a recent on-site inspection. This accreditation is awarded to facilities that meet the highest standards of quality in laboratory services. With this recognition, DermTech joins the prestigious ranks of some of the most prominent clinical laboratories in the world. This recognition adds to the certification of the clinical laboratory previously received from the Centers for Medicare & Medicaid Services (CMS) Clinical Laboratory Improvements Amendment (CLIA).
The CAP Laboratory Accreditation Program is an internationally recognized program and the only one of its kind to utilize teams of practicing laboratory professionals as inspectors. During the CAP accreditation process, inspectors perform an on-site inspection and examine the laboratory's records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, as well as overall management to ensure it meets CAP's stringent requirements. The goal of the CAP program is to improve patient safety by advancing through education and rigorous standards, which meet or exceed regulatory requirements.
"Receiving CAP accreditation and passing our on-site inspection with zero deficiencies is an important recognition of our laboratory's commitment to the quality of the results we provide to our physicians and patients," said Darryl Garrison, VP of Laboratory Operations.
DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected non-invasively using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.
Sarah Dennison, MBA
VP of Marketing
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermtech-receives-cap-accreditation-300254200.html
SOURCE DermTech, Inc.